Pure Global AI
NCT06261294Recruiting

OncoSweep Cancer Spotlight and Spectrum Product Line

CONQUER Cancer Study: To Collect Blood Samples From Cancer and Non-cancer Participants for Development and Validation of the 'OncoSweep Cancer Spotlight and Spectrum Product Line
Pharus Taiwan, Inc.ClinicalTrials.govdiagnostic test
Verified
Study focus
Disease/Condition
Lung Cancer
Drug/Device/Intervention
OncoSweep Lung Spotligh
Study type
Observational
Intervention type
diagnostic test
Sponsor & location
Primary sponsor
Pharus Taiwan, Inc.
Location
Taipei, Taiwan
Timeline & enrollment
Phase
N/A
Start date
May 23, 2023
End date
Mar 20, 2026
Enrollment
800 participants
Primary outcome

To differentiate lung cancer signals from non-cancer signals based on analysis of OncoSweep Lung Spotlight.

Summary

CONQUER cancer study: To collect blood samples from cancer and non-cancer participants for
 development and validation of the 'OncoSweep Cancer Spotlight and Spectrum Product Line'

ICD-10 classifications
Carcinoma in situ: Bronchus and lungSecondary malignant neoplasm of lungMalignant neoplasm of bronchus and lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm: Overlapping lesion of bronchus and lung
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06261294
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06261294 through Pure Global AI's free database. This phase not specified trial is sponsored by Pharus Taiwan, Inc. and is currently Recruiting. The study focuses on Lung Cancer. Target enrollment is 800 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.